hengrui glp 1 Oral Ribupatide Produces Up to 12% Weight Loss in Phase 2 Obesity Trial Kailera Therapeutics IPO: GLP-1 Obesity

Gastrointestinal Conditions BPC-157 was originally isolated from gastric juice, and its most robust preclinical evidence involves gastrointestinal healing

Athira failed to disclose allegations of research misconduct to the National Institutes of Health in grant applications that referenced the manipulated papers, including a grant NIH funded in 2019

Advances in the Understanding of Acetaminophen Toxicity Mechanisms: A Clinical Toxicology Perspective

The batch COA was easy to match to the vial label

It appears Dihexa is an excellent novel candidate molecule to augment peripheral nerve regeneration and functional recovery

The expanding world of oxidative protein folding